More Clarity Pharmaceuticals Ltd. news
Clarity Pharmaceuticals Ltd.ASX: CU6

S&P DJI Announces September 2025 Quarterly Rebalance

Sep 5, 2025 at 7:28 AM EDT · Issued by Clarity Pharmaceuticals Ltd.

Filed with ASX · Sep 5, 2025 at 7:28 AM EDT · 7 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-september-2025-quarterly-rebalance-14

Clarity Pharmaceuticals Ltd. on 6ix

Story so far

  • S&P DJI Announces December 2024 Quarterly RebalanceDec 6, 2024
  • S&P DJI Announces September 2024 Quarterly RebalanceSep 6, 2024
  • S&P DJI Announces March 2024 Quarterly RebalanceMar 1, 2024

Earlier from Clarity Pharmaceuticals

  • Preliminary Final ReportAug 28, 2025
  • Clarity successfully completes $203 million institutional plJul 28, 2025
  • Co-PSMA trial: Recruitment successfully completedJul 17, 2025
  • Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRxJun 17, 2025
  • Clarity enters a Commercial Manufacturing AgreementJun 16, 2025

Later from Clarity Pharmaceuticals

  • Co-PSMA trial achieves primary endpointOct 14, 2025
  • Clarity signs copper-67 Supply Agreement with NusanoOct 16, 2025
  • AGM MD PresentationNov 24, 2025
  • Positive guidance from the US FDA on Cu-64 SARTATE Phase IIIDec 21, 2025
  • Co-PSMA abstract accepted for oral presentation at EAUDec 23, 2025
All Clarity Pharmaceuticals news releases↗

Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.

Follow Clarity Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer